DNTH insider buying and SEC filings, explained
Dianthus Therapeutics, Inc. · CIK 1690585
Tracked: Forms 3/4/5, 8-K, NT · All filings on sec.gov
Insider activity in the last 12 months
Bought
$0
Insiders who bought
0
Sold (not marked 10b5-1)
$0
Planned sales (10b5-1)
$71.2M
Insider purchases and sales, last 12 months
| Traded | Type | What was filed | Source |
|---|---|---|---|
| Sep 17, 2026 | Planned (10b5-1) | Edward Carr (Chief Accounting Officer) sold 20,000 shares at about $101.38 ($2.0M), marked as a 10b5-1 plan trade. Holdings down 100% to 0 shares. | SEC filing Filed Sep 18, 2026 |
| Sep 1, 2026 | Planned (10b5-1) | Simrat Randhawa (EVP, Head of R&D) sold 23,124 shares at about $106.41 ($2.5M), marked as a 10b5-1 plan trade. Holdings down 85% to 4,000 shares. | SEC filing Filed Sep 3, 2026 |
| Aug 19, 2026 | Planned (10b5-1) | Simon Read (Director) sold 2,778 shares at about $117.55 ($327K), marked as a 10b5-1 plan trade. Holdings down 100% to 0 shares. | SEC filing Filed Aug 19, 2026 |
| Aug 10, 2026 | Planned (10b5-1) | Anne McGeorge (Director) sold 7,750 shares at about $109.01 ($845K), marked as a 10b5-1 plan trade. Holdings down 100% to 0 shares. | SEC filing Filed Aug 11, 2026 |
| Aug 10, 2026 | Planned (10b5-1) | Simon Read (Director) sold 2,777 shares at about $109.55 ($304K), marked as a 10b5-1 plan trade. Holdings down 100% to 0 shares. | SEC filing Filed Aug 11, 2026 |
| Aug 7–10, 2026 | Planned (10b5-1) | Adam M Veness (SVP, General Counsel and Sec.) sold 20,000 shares between Aug 7 and Aug 10 at about $110.44 ($2.2M), marked as a 10b5-1 plan trade. Holdings down 100% to 0 shares. | SEC filing Filed Aug 11, 2026 |
| Aug 7, 2026 | Planned (10b5-1) | Marino Garcia (CEO and Director) sold 166,000 shares at about $108.11 ($17.9M), marked as a 10b5-1 plan trade. Holdings down 72% to 65,292 shares. | SEC filing Filed Aug 7, 2026 |
| Jul 9, 2026 | Planned (10b5-1) | Ryan Savitz (CFO) sold 31,249 shares at about $101.03 ($3.2M), marked as a 10b5-1 plan trade. Holdings down 100% to 0 shares. | SEC filing Filed Jul 13, 2026 |
| Jun 17, 2026 | Planned (10b5-1) | Adam M Veness (SVP, General Counsel and Sec.) sold 30,000 shares at about $80.80 ($2.4M), marked as a 10b5-1 plan trade. Holdings down 100% to 0 shares. | SEC filing Filed Jun 18, 2026 |
| Jun 1, 2026 | Planned (10b5-1) | Simrat Randhawa (EVP, Head of R&D) sold 26,530 shares at about $90.62 ($2.4M), marked as a 10b5-1 plan trade. Holdings down 87% to 4,000 shares. | SEC filing Filed Jun 2, 2026 |
| May 8, 2026 | Planned (10b5-1) | Paula Soteropoulos (Director) sold 599 shares at $85.47 ($51K), marked as a 10b5-1 plan trade. Holdings down 100% to 0 shares. | SEC filing Filed May 11, 2026 |
| Apr 9, 2026 | Planned (10b5-1) | Ryan Savitz (CFO) sold 8,224 shares at about $89.84 ($739K), marked as a 10b5-1 plan trade. Holdings down 100% to 0 shares. | SEC filing Filed Apr 10, 2026 |
| Mar 31, 2026 | Planned (10b5-1) | Ryan Savitz (CFO) sold 114,367 shares at about $83.00 ($9.5M), marked as a 10b5-1 plan trade. Holdings down 100% to 0 shares. | SEC filing Filed Apr 1, 2026 |
| Mar 31, 2026 | Planned (10b5-1) | Paula Soteropoulos (Director) sold 599 shares at $80.11 ($48K), marked as a 10b5-1 plan trade. Holdings down 100% to 0 shares. | SEC filing Filed Apr 1, 2026 |
| Mar 24, 2026 | Planned (10b5-1) | Paula Soteropoulos (Director) sold 27,594 shares at $78.05 ($2.2M), marked as a 10b5-1 plan trade. Holdings down 100% to 0 shares. | SEC filing Filed Mar 26, 2026 |
| Mar 12, 2026 | Planned (10b5-1) | Simrat Randhawa (EVP, Head of R&D) sold 33,830 shares at $81.48 ($2.8M), marked as a 10b5-1 plan trade. Holdings down 100% to 0 shares. | SEC filing Filed Mar 13, 2026 |
| Mar 12, 2026 | Planned (10b5-1) | Marino Garcia (CEO and Director) sold 122,918 shares at about $81.49 ($10.0M), marked as a 10b5-1 plan trade. Holdings down 100% to 0 shares. | SEC filing Filed Mar 13, 2026 |
| Mar 12, 2026 | Planned (10b5-1) | Edward Carr (Chief Accounting Officer) sold 43,682 shares at about $81.49 ($3.6M), marked as a 10b5-1 plan trade. Holdings down 100% to 0 shares. | SEC filing Filed Mar 13, 2026 |
| Dec 4, 2025 | Planned (10b5-1) | Ryan Savitz (CFO) sold 20,000 shares at about $45.18 ($904K), marked as a 10b5-1 plan trade. Holdings down 100% to 0 shares. | SEC filing Filed Dec 5, 2025 |
| Nov 13–14, 2025 | Planned (10b5-1) | Simrat Randhawa (EVP, Head of R&D) sold 196,538 shares between Nov 13, 2025 and Nov 14, 2025 at about $37.55 ($7.4M), marked as a 10b5-1 plan trade. Holdings down 98% to 4,000 shares. | SEC filing Filed Nov 14, 2025 |
34 routine transactions (such as grants, option exercises or tax withholding) are not listed.
Cluster buys
No cluster buys in the last 12 months.
Red flags
No red flags in the last 12 months.
Key events
No key events in the last 12 months.
8-K filings, last 12 months
No 8-K filings in the last 12 months.
Red flags are objective triggers only: the item or form filed, never an opinion.
Follow DNTH in the Insider Ledger app
Get the appA plain-English brief of insider purchases, 8-Ks and red flags at the companies you pick. No account needed.